PARK2
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
RB7371
unconjugated
Applikationshinweise
Western blot: 1/1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
10 mM HEPES ( pH 7.5), 150 mM NaCl, 100 μg/mL BSA and 50 % Glycerol.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
-20 °C
Informationen zur Lagerung
Store the antibody undiluted (in aliquots) at-20 °C.
Target
Parkin (PARK2)
(Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
Andere Bezeichnung
PARK2 / Parkin
Hintergrund
Parkin is an E3 ligase in the ubiquitin-proteasome system. Hereditary Parkinson's disease is most commonly caused by mutations in the parkin gene and is characterized by the progressive loss of dopaminergic neurons and the presence of Lewy bodies in the substania nigra (Jenner et al.,1992). Recent evidence suggests that phosphorylation of parkin at Ser101 may have an important regulatory role on its E3 ubiquitin ligase activity (Yamamoto et al., 2005).Synonyms: AR-JP, E3 ubiquitin-protein ligase parkin, LPRS2, PDJ, PRKN, Parkinson disease 2, Parkinson juvenile disease protein 2